References

russjcardiol

Российский кардиологический журнал

Russian Journal of Cardiology

1560-40712618-7620

«SILICEA-POLIGRAF» LLC

10.15829/1560-4071-2018-10-127-135

russjcardiol-3081

Research Article

КЛИНИКА И ФАРМАКОТЕРАПИЯ

GUIDELINES FOR THE PRACTITIONER

Двойная антитромбоцитарная терапия у пациентов с острым коронарным синдромом. Результаты реальной клинической практики

Dual antiplatelet therapy in patients with acute coronary syndrome. Results of actual clinical practice

https://orcid.org/0000-0002-4642-3610

Барбараш

О. Л.

Barbarash

O. L.

Доктор медицинских наук, профессор, член-корреспондент РАН, директор; заведующий кафедрой кардиологии и сердечно-сосудистой хирургии.

https://orcid.org/0000-0003-3729-616X

Кашталап

В. В.

Kashtalap

V. V.

Доктор медицинских наук, заведующий лабораторией патофизиологии мультифокального атеросклероза; доцент кафедры кардиологии и сердечно-сосудистой хирургии.

v_kash@mail.ru

НИИ комплексных проблем сердечно-сосудистых заболеваний; Кемеровский государственный медицинский университет Минздрава РоссииРоссияResearch Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical Academy of the Ministry of HealthRussian Federation

2018

24112018

010127135

2018

Барбараш О.Л., Кашталап В.В.

Barbarash O.L., Kashtalap V.V.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://russjcardiol.elpub.ru/jour/article/view/3081

В обзорной статье представлено современное состояние вопроса использования двойной антитромбоцитарной терапии (ДАТТ) у пациентов с острым коронарным синдромом (ОКС) на основании современных клинических рекомендаций и в реальной клинической практике. Обсуждаются основные отличия в частоте использования и длительности ДАТТ в различных странах; приводится анализ характеристик пациентов, включенных в рандомизированные клинические исследования и популяции пациентов реальной клинической практики, принимающих ДАТТ после перенесенного ОКС. Использованы литературные источники из открытых баз данных PubMed, MEDLINE, eLibrary.

The review article presents the state-of-the-art of use of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) based on modern clinical guidelines and in actual clinical practice. The main differences in the frequency of use and duration of DAPT in different countries are discussed. The study included analysis of the characteristics of patients in randomized clinical trials and patients in actual clinical practice who take DATT after undergoing ACS. Literature sources from open databases PubMed, MEDLINE, eLibrary are used.

двойная антитромбоцитарная терапияострый коронарный синдромприверженность к терапии

dual antiplatelet therapyacute coronary syndromecompliance

References1

Барбараш О.Л., Каретникова В. Н., Кашталап В. В. Пациент после инфаркта миокарда: как снизить риск повторного ишемического события? Кардиосоматика. 2015; 6(2):12-9.

Barbarash OL, Karetnikova VN, Kashtalap VV. The patient after myocardial infarction: how to reduce a risk of recurrent ischemic event? Cardiosomatics. 2015; 6(2):12-9. (In Russ).

Green A, Pottegard A, Broe A, et al. Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study. BMJ Open. 2016 May 12;6(5):e010880. doi:10.1136/bmjopen-2015-010880.

Mulukutla SR, Marroquin OC, Vlachos HA, et al. Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry. Am J Cardiol. 2013;111(4):486-92. doi:10.1016/j.amjcard.2012.10.030.

Angeras O, Hasvold P, Thuresson M, et al. Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population- based cohort study. Scand Cardiovasc J. 2016;50(2):99-107 doi:10.3109/14017431.2015.1119304.

Patrono C, Morais J, Baigent C, et al. Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. J Am Coll Cardiol. 2017 Oct 3;70(14):1760-76. doi:10.1016/j.jacc.2017.08.037.

Costa F, van Klaveren D, James S, et al. PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025- 34. doi:10.1016/S0140-6736(17)30397-5.

Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735-49. doi:10.1001/jama.2016.3775.

Czarny MJ, Nathan AS, Yeh RW, et al. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol. 2014;37(8):505-13. doi:10.1002/clc.22289.

Mathews R, Wang TY, Honeycutt E, et al. TRANSLATE-ACS Study Investigators. Persistence with secondary prevention medications after acute myocardial infarction: Insightsfrom the TRANSLATE-ACS study. Am Heart J. 2015 Jul;170(1):62-9. doi:10.1016/j.ahj.2015.03.019.

Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2018;39:213-54. doi:101093/eurheartj/ehx419.

Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39:119-77. doi:10.1093/eurheartj/ehx393.

Kim K, Lee TA, Touchette DR, et al. Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome.J Manag Care Spec Pharm. 2017;23(1):57-63. doi:10.18553/jmcp.2017.23.1.57.

Riedmaier P, Hochade M, Ince H, et al. Comparative efficacy and safety of ticagrelor vs. prasugrel in patients undergoing PCI for NSTEACS.Results of the prospective ALKK- Registry Eur Heart J. 2017;38(Supplement),1263.

Sahlen A, Varenhorst C, Lagerqvist B, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016 Nov 21;37(44):3335-42. doi:10.1093/eurheartj/ehw284.

Эрлих А.Д., Грацианский Н.А. Российский регистр острого коронарного синдрома “РЕКОРД-3”. Характеристика пациентов и лечение до выписки из стационара. Кардиология. 2016;56:4. doi:10.18565/cardio.2016.4.16-24.

Erlikh AD, Gratsiansky NA. Registry of Acute Coronary Syndromes “RECORD-3”. Characteristics of Patients and Treatment Until Discharge During Initial Hospitalization. Kardiologiia. 2016;56:4. (In Russ.). doi:10.18565/cardio.2016.4.16-24.

Эрлих А.Д., Барбараш О.Л., Кашталап В.В., Грацианский Н.А. Степень следования клиническим руководствам при остром коронарном синдроме без подъема сегмента ST: связь с исходами, предикторы “плохого” лечения (результаты регистра РЕКОРД-3). Комплексные проблемы сердечно-сосудистых заболеваний. 2016;5(2):75-82.

Erlikh AD, Barbarash OL, Kashtalap VV, Gratsiansky NA. Compliance with clinical practice guidelines for non ST-segment elevation acute coronary syndrome: association between outcomes and predictors of poor management (RECORD-3 registry data). Complex Issues of Cardiovascular Diseases. 2016;5(2):75-82. (In Russ.).

Эрлих А.Д. от имени всех участников регистра РЕКОРД-3. 12-месячные исходы у пациентов с острым коронарным синдромом, включенных в Российский регистр РЕКОРД-3. Российский кардиологический журнал. 2018;23(3):23-30. doi:10.15829/1560-4071-2018-3-23-3.

Erlikh AD on behalf of the RECORD-3 registry workteam. Twelve months oucomes in patients with acute coronary syndrome, by the National registry RECORD-3. Russ J Cardiol. 2018;23(3):23-30. (In Russ.). doi:10.15829/1560-4071-2018-3-23-3.

Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57. doi:10.1056/NEJMoa0904327.

Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study Lancet. 2013 Nov 23;382(9906):1714-22. doi:10.1016/S0140-6736(13)61720-1.

Bagai A, Wang TY, Goodman SG, et al. Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. Canadian Observational AntiPlatelet sTudy (COAPT) Investigators. Int J Cardiol. 2017 Feb 1;228:459-464. doi:10.1016/j.ijcard.2016.11.240.

Claeys MJ, Beauloye C, Pourbaix S, et al. Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study. Rewinder Study Group. Eur Heart J Cardiovasc Pharmacother. 2017 Oct 1;3(4):189-97 doi:10.1093/ehjcvp/pvw043.

Czarny MJ, Nathan AS, Yeh RW, et al. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol 2014;37:505-13. doi:10.1002/clc.22289.

Molife C, Frech-Tamas F, DeKoven M, et al. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor. J Med Econ 2015;18:898-908. doi:10.3111/13696998.2015.1060979.

Simeone JC, Molife C, Marrett E, et al. Oneyear post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel. Am J Cardiovasc Drugs 2015;15:337-50. doi:10.1007/s40256-015-0147-y.

Zhu B, Zhao Z, McCollam P, et al. Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Curr Med Res Opin 2011;27:633-41. doi:10.1185/03007995.2010.551657.

Nordstrom BL, Simeone JC, Zhao Z, et al. Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention. Am J Cardiovasc Drugs 2013;13:263-71. doi:101007/s40256-013-0028-1.

Хомицкая ЮВ, Аверков ОВ, Руда МЯ. Долгосрочное наблюдение за подходами к антитромботической терапии у российских пациентов с острым коронарным синдромом: обсервационное исследование (EPICOR-RUS). Неотложная кардиология. 2017;2:23-36.

Khomitskaya YV, Averkov OV, Ruda MY. Long-term follow-up of antithrombotic management patterns in patients with acute coronary syndrome patients in Russia: an observational study (EPICOR-RUS study) Emergency Cardiology. 2017;2:23-36. (In Russ.).

Annemans L, Danchin N, Van de Werf F, et al. Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry. Open Heart. 2016;3(1):e000347. doi:10.1136/openhrt-2015-000347.eCollection2016.

Bonaca MP, Bhatt D, Cohen M, et al. for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. doi:10.1056/NEJMoa1500857.

Blin P, Dureau-Pournin C, Lassalle R, et al. Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database. Br J Clin Pharmacol. 2017 Sep;83(9):2056-65. doi:10.1111/bcp.13291.

Marenzi GS, Cosentino N, Campodonico J, et al. A new score for risk stratification of patients with acute myocardial infarction based on the PEGASUS-TIMI 54 criteria. JACC. 2017;69 (11):suppl 14.

Bonaca MP, Bhatt D, Braunwald E, et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS- TIMI 54) trial. Am Heart J. 2014;167:437-44.e5. doi:10.1016/j.ahj.2013.

Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: The treatment-risk paradox. JAMA. 2004;291:1864-70. doi:10.1001/jama.291.15.1864.

Алтарев СС, Барбараш ОЛ, Помешкина СА, и др. Причины отказа от проведения реперфузионной терапии у пациентов с острым коронарным синдромом с подъемом сегмента ST. Кардиология. 2012; 6:4-9.

Altarev SS, Barbarash OL, Pomeshkina SA, et al. Predictors of Non-Fulfillment of Reperfusion Therapy in Patients With ST-Elevation Acute Coronary Syndrome. Kardiologiia. 2012; 6:4-9. (In Russ.).

Ferlini M, Musumeci G, Grieco N, et al. The paradox of clopidogrel use in patients with acute coronary syndromes and diabetes: insightfrom the Diabetes and Acute Coronary Syndrome Registry. Coron Artery Dis. 2018 Jun;29(4):309-15. doi:10.1097/MCA.0000000000000601.

The authors declare that there are no conflicts of interest present.